

analysis of the intensity of ninhydrine rings obtained with amino acid standards of 10–20 $\mu\text{g}/\text{ml}$, referred to as +. At the end of each experiment the sterile conditions of the mixtures were controlled by agar plate tests either for bacteria or for fungi.

Results. Of the catalysts examined, CuSO_4 is the most active in producing different amino acids both at 0.05 and 0.1%, especially when nitrogen is supplied by an inorganic source. This synthesis, as well as in the presence of the other catalysts, is characterized by the appearance and disappearance of definite amino acids during the irradiation time with the prevalence of some amino acids. An example of such behaviour is reported in Table I.

The further results with CuSO_4 , with FeCl_3 at 0.05 and 0.1% (also an active catalyst), and with CoCl_2 (a good catalyst at 0.05%), are summarized in Table II.

An attempt to potentiate the yield of photochemical synthesis of amino acids has been successful: mixing CoCl_2 0.05% and FeCl_3 0.05% in mixtures where air was the nitrogen source. Here, only glycine and alanine are formed at the beginning and last up to 30 days of light exposure. NiCO_3 is practically inactive.

The non-identified ninhydrin rings were presumably due to peptide formation. The tests on the samples kept in the dark showed formation of amino acids detectable in very faint rings with Rf values different from those of photochemically synthesized amino acids.

The mechanism of formation and transformation of amino acids following photocatalysis is not as yet known. Accordingly, it is difficult to understand the prevailing formation of some particular amino acid by the action of specific catalysts. The sterility, controlled carefully throughout the experiments, is a clear indication that formation and transformation of amino acids can occur under abiogenic conditions, as was observed also by MILLER⁵ using CH_4 and NH_3 in a cycled system catalysed by electric discharge, and by CULTRERA and FERRARI⁶

from glucides and organic acids excited by UV-light. The importance of such a type of photochemical synthesis has been further underscored by recent observations by BAHADUR et al.⁷, confirmed by BRIGGS⁸, demonstrating that the action of sunlight or of artificial light on sterilized solutions containing mixtures of amino acids and organic catalysts can bring about the formation of units having properties of growth, division and metabolic activity, henceforth called *Jeevanu* (which in Sanskrit means particles of life)⁹.

Riassunto. Viene confermato che la sintesi fotochimica degli aminoacidi da paraformaldeide catalizzata da composti inorganici avviene sia in presenza sia in assenza di una sorgente inorganica di azoto fissato (aria). Inoltre viene dimostrato che i tipi di aminoacidi prodotti come la velocità di formazione dipendono dal catalizzatore usato.

LEONIDA SANTAMARIA and L. FLEISCHMANN

Cattedra di Patologia Generale, Facoltà di scienze dell'Università, Sassari (Italy), July 26, 1965.

⁵ S. L. MILLER, *Science* 117, 528 (1953).

⁶ R. CULTRERA and G. FERRARI, *Annali Chim.* 49, 1639 (1959).

⁷ K. BAHADUR, H. C. VERMA, R. B. SRIVASTAVA, K. M. L. AGRAWAL, R. S. PANDEY, INDRA SAXENA, A. N. MALVIYA, VINOD KUMAR, O. N. PERTI, and H. D. PATHAK, *Zentbl. Bakt. Parasitkde.* 117, 575 (1964).

⁸ H. M. BRIGGS, Communication at the IVth Int. Congress of Photobiology, Oxford (1964), appearing in the *J. Br. Interplanet. Soc.*

⁹ Acknowledgments: This work was carried out mainly in the Institute of General Pathology of the University of Milan. The authors are grateful for the interest and partial support from Professor E. CIARANFI, Director of the Institute.

Studies on the Metabolic Fate of the ^{14}C -Labeled Methyl Group of a Methylhydrazine Derivative in P815 Mouse Leukemia

Experimental and clinical evaluation of the cytotoxic agent 1-methyl-2-*p*-(isopropylcarbamoyl)benzylhydrazine hydrochloride (MBH) (NSC 77213) evoked an interest in its reaction mechanism and metabolism. The coincidence of cytotoxic¹, carcinogenic², and teratogenic effects³ revealed a probable attack on the genetic material of the cell, and the breakdown in vivo of DNA by MBH⁴ stimulated the search in the same direction. Our interest in this compound was increased by our observation that the terminal N-methyl group was labile⁵ and by the considerable interest and speculation as to the biological significance of the normally occurring methylation of RNA and DNA in many species.

The aim of this investigation was to compare the potencies and limits of the formate pool of the mammalian cells in vivo with that of the C_1 -unit derived from the N-methyl group of MBH, and to search for methylated and unmethylated purine bases in the urine of P815 leukemic mice treated either with ^{14}C -MBH or ^{14}C -Na formate.

Materials and methods. The two ^{14}C -labeled compounds, MBH (labeled in the terminal N-methyl group) and Na

formate, showed a specific activity of 17.0 $\mu\text{C}/\text{mg}$ and 74 $\mu\text{C}/\text{mg}$, respectively⁶. Both substances were dissolved in 0.9% saline. 2 series of 30 BDF₁ mice each, ranging in weight from 20–25 g, were inoculated intraperitoneally with 10 million P815 leukemic cells on day 0. On day 6, a group of 10 mice from each series was injected i.p. with 33.33 mg/kg (0.129 mM/kg) of ^{14}C -MBH and 1.47 mg/kg (0.0216 mM/kg) of ^{14}C -Na formate, respectively. The urine of these mice was collected in ice-cooled flasks over a 24 h period. The remaining 20 mice from each series were injected with the same doses of either ^{14}C -MBH or ^{14}C -Na formate on day 7. Their urine was collected 5 h

¹ W. BOLLAG and E. GRÜNBERG, *Experientia* 19, 130 (1963).

² M. G. KELLY, R. W. O'GARA, K. GADEKAR, S. T. YANCEY, and V. T. OLIVERIO, *Cancer Chemother. Rep.* 39, 77 (1964).

³ S. CHAUBE and M. L. MURPHY, *Proc. Amer. Assoc. Cancer Res.* 5, 11 (1964).

⁴ K. BERNEIS, M. KOFLER, W. BOLLAG, A. KAISER, and A. LANGEMANN, *Experientia* 19, 132 (1963).

⁵ W. KREIS and W. YEN, *Experientia* 21, 284 (1965).

⁶ ^{14}C -MBH was kindly supplied by F. Hoffmann-La Roche AG, Basel (Switzerland) through the courtesy of Dr. W. BOLLAG. ^{14}C -Na formate was purchased from New England Nuclear Corporation, Boston, Mass.

following injection of the drugs. The 5 h and 24 h urines of both series were then pooled separately for the extraction studies.

The purine bases were isolated from urine following the procedure described by WEISSMANN et al.⁷ The final separation of the bases was effected using the systems of MARKHAM and SMITH⁸ and HOTCHKISS⁹. The spots were extracted from the paper chromatograms with 0.1N HCl, rechromatographed on Whatman paper either in the *n*-butanol-HCOOH-water⁸ or a phosphate buffer system¹⁰ and eluted with water. The complete UV-spectrum of these extracts was determined as described by WEISSMANN et al.⁷. An aliquot of the basic solution was added immediately to 10 ml of diatol¹¹, and the radioactivity was then measured. The specific activities were evaluated as cpm/optical density at the wavelength of the maximum at pH 2.1¹². The UV-absorption spectra were compared with known samples of guanine, adenine, hypoxanthine 7-methylguanine, 1-methyladenine (compound S of WEISSMANN⁷), and methylhypoxanthine, run in the same paper-chromatography system and extracted and evaluated as above¹³.

Results and discussion. As shown in the Table, after i.p. injection of both ¹⁴C-MBH and ¹⁴C-Na formate, guanine and 7-methylguanine, adenine and 1-methyladenine, hypoxanthine and 1-methylhypoxanthine were found in the 24 h urine (xanthine, but not 7-methylxanthine, was also identified). Several studies indicate that in bacteria^{14,15} and Ehrlich ascites cells¹⁶ the methyl group for the methylated trace bases of s-RNA originates primarily from the methyl group of methionine. If this were also true for mammals, we would expect in an experiment, in which ¹⁴C-Na formate is used as the sole labeled precursor for purine bases, that methylation of guanine and adenine would not influence the ratios of the specific activity of the methylated to unmethylated bases, i.e. we were to expect a ratio of 1. In the ¹⁴C-Na formate experiment, as demonstrated in the Table, the ratios of the specific activity of 1-methyladenine to adenine, and 1-methylhypoxanthine to hypoxanthine (0.99 and 0.94, respectively) come close to the theoretically expected value, whereas the ratio of 7-methylguanine to guanine (2.9) obviously does not. This suggests that ¹⁴C-Na formate not only enters the formate pool for use in the de novo synthesis of the C₂ and C₈ positions of the purine bases, but that one part of ¹⁴C-Na formate might be transferred either *directly* onto the 7-position of guanine (including a step of reduction) or through the formate pool onto homocysteine, as reported by BERG¹⁷, with subsequent transmethylation of the methyl group of the resulting methionine onto guanine. Although the result of these two, or

any other, processes is the same, namely labeled 7-methylguanine, the difference in the specific activities indicates a preference of one of these metabolic pathways or a different size of the pools. A further, but slight, possibility might be a rapid excretion of 7-methylguanine, whereas guanine itself might be re-used for the synthesis of DNA and RNA. However, we would expect a re-use not only of guanine but also of adenine, which is not the case, as the results show. The selective deviation from the expected ratio of the specific activities, as demonstrated here for 7-methylguanine to guanine only, might well be the expression of the more ready accessibility of guanine for methylation or, in general, alkylation. This phenomenon is well known for the alkylation of DNA¹⁸⁻²⁰ and RNA²⁰ in vitro with various methylating and alkylating agents and was predicted for in vivo studies by LAWLEY²⁰

⁷ B. WEISSMANN, P. A. BROMBERG, and A. B. GUTMAN, *J. biol. Chem.* **224**, 407 (1957).

⁸ R. MARKHAM and J. D. SMITH, *Biochem. J.* **45**, 294 (1949).

⁹ R. D. HOTCHKISS, *J. biol. Chem.* **175**, 315 (1948).

¹⁰ S. ZAMENHOF, G. BRAWERMAN, and E. CHARGAFF, *Biochim. biophys. Acta* **9**, 402 (1952).

¹¹ R. J. HERBERG, *Anal. Chem.* **32**, 42 (1960).

¹² No attempt was made to calculate the specific activity/m μ m, since the molar extinction [ϵ] for the conditions reported by WEISSMANN et al.⁷ was known only for 7-methylguanine, guanine, adenine, and hypoxanthine, but not for 1-methyladenine and 1-methylhypoxanthine. Also, only a small difference was seen in the factors of specific activity of 7-methylguanine to specific activity of guanine, when the values of the ¹⁴C-Na formate experiment were calculated on a molar ratio compared to the one per optical density (2.6 versus 2.9).

¹³ The authors are indebted to Dr. ROSS H. HALL, Roswell Park Memorial Institute, Buffalo, N.Y., for samples of 1-methylguanine, 1-methylinosine, and 1-methyladenosine. The free bases 1-methylhypoxanthine and 1-methyladenine were obtained by boiling 1-methylinosine and 1-methyladenosine in 0.5N HCl for 1 h. 7-Methylguanine and hypoxanthine were purchased from Cyclo Chemical Corporation, Los Angeles, California. Adenine and guanine were purchased from Nutritional Biochemical Corporation, Cleveland, Ohio.

¹⁴ L. R. MANDEL and E. BOREK, *Biochem. biophys. Res. Commun.* **4**, 14 (1961).

¹⁵ P. R. SRINIVASAN and E. BOREK, *Science* **145**, 548 (1964).

¹⁶ B. B. BISWAS, M. EDMONDS, and R. ABRAMS, *Biochem. biophys. Res. Commun.* **6**, 146 (1961).

¹⁷ P. BERG, *J. biol. Chem.* **205**, 145 (1953).

¹⁸ P. D. LAWLEY and C. A. WALLICK, *Chem. Ind.* **1957**, 633.

¹⁹ P. D. LAWLEY, *Biochim. biophys. Acta* **26**, 450 (1957).

²⁰ P. D. LAWLEY, in *Proc. 11th Ann. Reunion, Société de Chimie Physique*, 1961 (Pergamon Press, Oxford-New York 1962), p. 132.

Comparison of specific activity of purine bases found in the urine of BDF₁ mice with P815 leukemia after treatment with ¹⁴C-MBH and ¹⁴C-Na formate

Purine bases	Urine of mice treated with ¹⁴ C-MBH		Urine of mice treated with ¹⁴ C-Na formate	
	Specific activity (cpm/optical density)	Ratio of specific activity of methylated to unmethylated base	Specific activity (cpm/optical density)	Ratio of specific activity of methylated to unmethylated base
7-Methylguanine	1505	24.3	1392	2.9
Guanine	62		482	
1-Methyladenine	314	7.9	367	0.99
Adenine	40		370	
1-Methylhypoxanthine	326	4.3	1612	0.94
Hypoxanthine	76		1722	

and confirmed by MAGEE and FARBER²¹ for DNA and RNA in rats. Although in vitro alkylation of nucleosides and nucleotides of guanine¹⁸ and deoxynucleotides¹⁹ can also be achieved, the general belief today is that the alkylation in vivo takes place at the level of the macromolecules^{16, 21-23}.

When the patterns of the urinary purines of ¹⁴C-MBH-treated and ¹⁴C-Na formate-treated mice are compared, the most striking difference is the more than 8 times higher ratio of the specific activity of 7-methylguanine to guanine (24.3) in the ¹⁴C-MBH experiment, whereas the ratios of the specific activity of 1-methyladenine to adenine and its metabolic product 1-methylhypoxanthine to hypoxanthine are much lower (7.9 and 4.3, respectively).

These results suggest that the methyl group of MBH not only contributes to the formate pool but is also transferred by by-passing the pool either (and most probably) by a direct transmethylation, or possibly by the route (a) homocysteine → (b) methionine → (c) guanine and adenine; (a) and (c) serve as acceptors and (b) as transmitter of the methyl group.

It is interesting that in a recently published study of the fate of the ¹⁴C-labeled methyl group of (methyl-¹⁴C-)methionine, MANDEL et al.²⁴ reported the identification of the same unmethylated and methylated bases in the urine of mice carrying mammary carcinoma as in our studies with P815 leukemic mice. Further studies will be needed to prove or disprove a possible connection between the metabolic pathways of the methyl group of methionine and MBH²⁵.

Zusammenfassung. Neben der bereits beschriebenen teilweisen Oxydation der endständigen N-Methylgruppe von

1-Methyl-¹⁴C-2-*p*-(isopropylcarbamoyl)benzylhydrazin-Hydrochlorid (MBH) (NSC 77213) in vivo⁵ lassen die hier aufgeführten Resultate auch auf eine Transmethylierung dieser Methylgruppe schliessen.

W. KREIS, SUSAN B. PIEPHO,
and HANNAH V. BERNHARD

Divisions of Experimental and Clinical Chemotherapy, Sloan-Kettering Institute for Cancer Research, and Sloan-Kettering Division of Cornell University Medical College, New York (N.Y., USA), March 22, 1966.

²¹ P. N. MAGEE and E. FARBER, *Biochem. J.* **83**, 114 (1962).

²² J. L. STARR, *Biochim. biophys. Acta* **67**, 676 (1962).

²³ M. GOLD, J. HURWITZ, and M. ANDERS, *Biochem. biophys. Res. Commun.* **11**, 107 (1963).

²⁴ L. R. MANDEL, P. R. SRINIVASAN, and E. BOREK, *Nature* **209**, 586 (1966).

²⁵ Acknowledgments: These studies were supported in part by U.S.P.H.S. Research Contract No. SA-43-ph-2445, Cancer Chemotherapy National Service Center, National Cancer Institute, and U.S.P.H.S. Research Grant No. CA-05826-02, National Cancer Institute; NCI Grant No. CA 08748; by Research Grant No. T 45, American Cancer Society, Delaware Division; and the Campbell Townsend Memorial Grant for Cancer Research from the American Cancer Society. The authors are indebted to Drs. J. H. BURCHENAL, D. A. KARNOFSKY, and I. H. KRACKOFF for their interest in this work; to Dr. A. BENDICH for helpful discussions; and to Dr. W. E. SCOTT of Hoffmann-La Roche Inc., Nutley, N.J., for the supply of unlabeled MBH (Natulan) (Ro 4-6467). We also thank Miss DOROTHY NARY for her skilful technical assistance.

Effect of Menadione on the Phagocytic Activity of Guinea-Pig Polymorphonuclear Leucocytes

Previous work¹ has shown that menadione, an electron acceptor for the oxidation of pyridin nucleotides through the flavoprotein DT-diaphorase², strongly increases the oxygen uptake of resting polymorphonuclear leucocytes. The menadione-stimulated respiration is amytal-, rotenone-, antimycin A- and cyanide-insensitive, and it is inhibited by dicoumarol at low concentration. The increased oxidation of NADPH₂ by menadione stimulates the oxidation of glucose through the hexosemonophosphate pathway.

The present communication deals with the finding that menadione is a powerful inhibitor of phagocytosis by polymorphonuclear leucocytes and with experiments carried out in an attempt to investigate the mechanism of such inhibition.

Experimental. The experiments on phagocytosis (incubation and cytological examinations) and on metabolic assays were performed as described previously^{1,3,4}, using guinea-pig polymorphonuclear leucocytes from sterile peritoneal exudate.

Results. (1) Effect of menadione on phagocytosis and its metabolic concomitants in aerobiosis. The addition of menadione 10⁻⁴M, 2 · 10⁻⁴M to leucocytes incubated in different conditions (Krebs-Ringer phosphate without CaCl₂, Krebs-Ringer bicarbonate without CaCl₂, tris-buffered NaCl-KCl solution) inhibits phagocytosis of

killed opsonized *Staphylococcus aureus* and *Bacillus subtilis*. The extent of inhibition was 80–90% over 30 experiments with different batches of cells. The addition of bacteria fails to stimulate the oxygen uptake and the C¹⁴O₂ production from glucose-U-C¹⁴ when menadione is present (Table 1).

Dicoumarol 10⁻⁵M, 10⁻⁷M slightly increases the respiratory activity of resting cells and has no effect on the extent of phagocytosis. In the presence of dicoumarol, the effect of menadione on the leucocytic respiration is abolished, whereas phagocytosis remains inhibited (Table I).

(2) Effect of menadione on aerobic glycolysis. There are many indications⁵⁻⁷ on the important energy-supplying role of aerobic glycolysis for phagocytosis in polymorphonuclear leucocytes.

The aerobic production of lactic acid is slightly inhibited by menadione even in the presence of dicoumarol.

¹ F. ROSSI and M. ZATTI, *Br. J. exp. Pathol.* **45**, 548 (1964).

² L. ERNSTER, L. DANIELSON, and M. LJUNGREN, *Biochim. biophys. Acta* **58**, 171 (1962).

³ F. ROSSI and M. ZATTI, *Experientia* **20**, 21 (1964).

⁴ F. ROSSI, M. ZATTI, and G. ZOPPI, *Experientia* **21**, 14 (1965).

⁵ H. BECKER, G. MUNDER, and H. FISCHER, *Hoppe-Seyler's Z. physiol. Chem.*, **313**, 266 (1958).

⁶ A. J. SBARRA and M. L. KARNOVSKY, *J. biol. Chem.* **234**, 1355 (1959).

⁷ Z. A. COHN and S. I. MORSE, *J. exptl. Med.* **111**, 667 (1960).